Les équipes

Principales publications

Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F. Early inhibition of hepatocyte innate responses by hepatitis B virus.  J Hepatol. 2015 Jul 26. pii: S0168-8278(15)00477-8. doi: 10.1016/j.jhep.2015.07.014. [Epub ahead of print]

Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, Rivoire M, Fletcher S, Javanbakht H, Lucifora J, Zoulim F, Durantel D.
Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. J Hepatol. 2015 Nov;63(5):1077-85. doi: 10.1016/j.jhep.2015.06.022. Epub 2015 Jul 3.

Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Epub 2014 Dec 5. PubMed PMID: 25482330.

 
 
Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28. PubMed PMID: 25176615.


Brault C, Lévy P, Duponchel S, Michelet M, Sallé A, Pécheur EI, Plissonnier ML, Parent R, Véricel E, Ivanov AV, Demir M, Steffen HM, Odenthal M, Zoulim F, Bartosch B. Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity. Gut. 2014 Dec 16. pii: gutjnl-2014-307904. doi: 10.1136/gutjnl-2014-307904. [Epub ahead of print] PubMed
PMID: 25516417.
 
 
Charuworn P, Hengen PN, Aguilar Schall R, Dinh P, Ge D, Corsa A, Reesink HW, Zoulim F, Kitrinos KM. Baseline Interpatient Hepatitis B Viral Diversity Differentiates HBsAg Outcomes in Patients Treated With Tenofovir Disoproxil Fumarate. J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00926-X. doi: 10.1016/j.jhep.2014.12.008. [Epub ahead of print] PubMed PMID: 25514556.
 
 
 
Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; for the VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B:limited role for risk scores in Caucasians. Gut. 2014 Jul 10. pii: gutjnl-2014-307023. doi: 10.1136/gutjnl-2014-307023. [Epub ahead of print] PubMed PMID: 25011935.


Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014 Mar 14;343(6176):1221-8. doi:  10.1126/science.1243462. Epub 2014 Feb 20. PubMed PMID: 24557838.


Lavocat F, Deny P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013 Jun 3. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013 Jun;12(6):447-64. 


Simonin Y, Vegna S, Akkari L, Gregoire D, Antoine E, Piette J, Floc'h N, Lassus P, Yu GY, Rosenberg AR, Karin M, Durantel D, Hibner U. Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis. PLoS Pathog. 2013 Mar;9(3):e1003234. 


Accardi R, Fathallah I, Gruffat H, Mariggi√≤ G, Le Calvez-Kelm F, Voegele C, Bartosch B, Hernandez-Vargas H, McKay J, Sylla BS, Manet E, Tommasino M. Epstein - Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog. 2013 Mar;9(3):e1003186. 


Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology. 2013 Mar 6. 


Jammart B, Michelet M, Pecheur EI, Parent R, Bartosch B, Zoulim F, Durantel D. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol. 2013 May;87(9):5065-80. 


Hayer J, Jadeau F, Deleage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013 Jan;41(Database issue):D566-70. 


Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012 Apr;12(4):341-53. 


Billioud G, Pichoud C, Parent R, Zoulim F. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. J Hepatol. 2012 Jun;56(6):1269-75. 


Zoulim F. Hepatitis: Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2011 Jul 4;8(7):366-7.

Lavocat F, Deny P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol. 2013 Jun 3. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013 Jun;12(6):447-64. Simonin Y, Vegna S, Akkari L, Gregoire D, Antoine E, Piette J, Floc'h N, Lassus P, Yu GY, Rosenberg AR, Karin M, Durantel D, Hibner U. Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis. PLoS Pathog. 2013 Mar;9(3):e1003234. Accardi R, Fathallah I, Gruffat H, Mariggi√≤ G, Le Calvez-Kelm F, Voegele C, Bartosch B, Hernandez-Vargas H, McKay J, Sylla BS, Manet E, Tommasino M. Epstein - Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog. 2013 Mar;9(3):e1003186. Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology. 2013 Mar 6. Jammart B, Michelet M, Pecheur EI, Parent R, Bartosch B, Zoulim F, Durantel D. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. J Virol. 2013 May;87(9):5065-80. Hayer J, Jadeau F, Deleage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013 Jan;41(Database issue):D566-70. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012 Apr;12(4):341-53. Billioud G, Pichoud C, Parent R, Zoulim F. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. J Hepatol. 2012 Jun;56(6):1269-75. Zoulim F. Hepatitis: Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2011 Jul 4;8(7):366-7.



Contenu